Study of Unresectable HCC Treated Concomitantly With TACE and Sorafenib in Chinese Patients
Phase of Trial: Phase IV
Latest Information Update: 08 May 2017
At a glance
- Drugs Sorafenib (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SUCCESS
- Sponsors Bayer
- 04 May 2017 Status changed from active, no longer recruiting to completed.
- 15 Mar 2017 Planned End Date changed from 1 Jan 2017 to 31 May 2017.
- 12 Dec 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017.